Do alprazolam-induced changes in saccadic eye movement and psychomotor function follow the same time course?

Patricia D. Kroboth, M. Margaret Folan, Kenneth S. Bauer, William Tullock, C. Eugene Wright, John A. Sweeney

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The purpose of this study was to determine whether short-term tolerance develops to GABA-agonist-induced changes in saccadic eye movements (SEMs), and whether the time course for GABA-agonist induced onset and offset of impairment is similar for SEMs and for psychomotor function. An additional goal was to determine whether there are differences in sensitivity between SEMs and psychomotor function. Six healthy volunteers participated in this balanced double-blind, three-way crossover, single-dose study of placebo and two different dosage forms of the GABA-agonist alprazolam: a rapidly absorbed oral 1.5-mg compressed tablet (CT) and a 3.0-mg sustained release (SR) tablet. Treatments were separated by a 7-day washout period. Peak concentrations did not differ between CT and SR treatments, although area under the concentration-time curve (AUC) of alprazolam was greater after administration of SR than after CT, because plateau concentrations were attained after SR. Both SEM and psychomotor tests showed time-dependent responses consistent with the development of tolerance. SEMs discriminated the differences in rate of drug input of the CT and SR formulations, with impairment evident at low concentrations during absorption. SEM impairment also persisted longer than did psychomotor impairment. Peak saccade velocity is a more sensitive indicator of pharmacologic effects mediated by the GABA- benzodiazepine receptor complex than are psychomotor responses. This is probably the result of the very high GABA dependency of SEMs, along with their limited sensitivity to motivation.

Original languageEnglish (US)
Pages (from-to)337-346
Number of pages10
JournalJournal of Clinical Pharmacology
Volume38
Issue number4
StatePublished - Apr 1998

Fingerprint

Alprazolam
Saccades
Tablets
GABA Agonists
Psychomotor Disorders
Dosage Forms
GABA-A Receptors
gamma-Aminobutyric Acid
Motivation
Healthy Volunteers
Placebos

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Kroboth, P. D., Folan, M. M., Bauer, K. S., Tullock, W., Wright, C. E., & Sweeney, J. A. (1998). Do alprazolam-induced changes in saccadic eye movement and psychomotor function follow the same time course? Journal of Clinical Pharmacology, 38(4), 337-346.

Do alprazolam-induced changes in saccadic eye movement and psychomotor function follow the same time course? / Kroboth, Patricia D.; Folan, M. Margaret; Bauer, Kenneth S.; Tullock, William; Wright, C. Eugene; Sweeney, John A.

In: Journal of Clinical Pharmacology, Vol. 38, No. 4, 04.1998, p. 337-346.

Research output: Contribution to journalArticle

Kroboth, PD, Folan, MM, Bauer, KS, Tullock, W, Wright, CE & Sweeney, JA 1998, 'Do alprazolam-induced changes in saccadic eye movement and psychomotor function follow the same time course?', Journal of Clinical Pharmacology, vol. 38, no. 4, pp. 337-346.
Kroboth, Patricia D. ; Folan, M. Margaret ; Bauer, Kenneth S. ; Tullock, William ; Wright, C. Eugene ; Sweeney, John A. / Do alprazolam-induced changes in saccadic eye movement and psychomotor function follow the same time course?. In: Journal of Clinical Pharmacology. 1998 ; Vol. 38, No. 4. pp. 337-346.
@article{df64bb0dc0c941fc80671c71372ebb92,
title = "Do alprazolam-induced changes in saccadic eye movement and psychomotor function follow the same time course?",
abstract = "The purpose of this study was to determine whether short-term tolerance develops to GABA-agonist-induced changes in saccadic eye movements (SEMs), and whether the time course for GABA-agonist induced onset and offset of impairment is similar for SEMs and for psychomotor function. An additional goal was to determine whether there are differences in sensitivity between SEMs and psychomotor function. Six healthy volunteers participated in this balanced double-blind, three-way crossover, single-dose study of placebo and two different dosage forms of the GABA-agonist alprazolam: a rapidly absorbed oral 1.5-mg compressed tablet (CT) and a 3.0-mg sustained release (SR) tablet. Treatments were separated by a 7-day washout period. Peak concentrations did not differ between CT and SR treatments, although area under the concentration-time curve (AUC) of alprazolam was greater after administration of SR than after CT, because plateau concentrations were attained after SR. Both SEM and psychomotor tests showed time-dependent responses consistent with the development of tolerance. SEMs discriminated the differences in rate of drug input of the CT and SR formulations, with impairment evident at low concentrations during absorption. SEM impairment also persisted longer than did psychomotor impairment. Peak saccade velocity is a more sensitive indicator of pharmacologic effects mediated by the GABA- benzodiazepine receptor complex than are psychomotor responses. This is probably the result of the very high GABA dependency of SEMs, along with their limited sensitivity to motivation.",
author = "Kroboth, {Patricia D.} and Folan, {M. Margaret} and Bauer, {Kenneth S.} and William Tullock and Wright, {C. Eugene} and Sweeney, {John A.}",
year = "1998",
month = "4",
language = "English (US)",
volume = "38",
pages = "337--346",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Do alprazolam-induced changes in saccadic eye movement and psychomotor function follow the same time course?

AU - Kroboth, Patricia D.

AU - Folan, M. Margaret

AU - Bauer, Kenneth S.

AU - Tullock, William

AU - Wright, C. Eugene

AU - Sweeney, John A.

PY - 1998/4

Y1 - 1998/4

N2 - The purpose of this study was to determine whether short-term tolerance develops to GABA-agonist-induced changes in saccadic eye movements (SEMs), and whether the time course for GABA-agonist induced onset and offset of impairment is similar for SEMs and for psychomotor function. An additional goal was to determine whether there are differences in sensitivity between SEMs and psychomotor function. Six healthy volunteers participated in this balanced double-blind, three-way crossover, single-dose study of placebo and two different dosage forms of the GABA-agonist alprazolam: a rapidly absorbed oral 1.5-mg compressed tablet (CT) and a 3.0-mg sustained release (SR) tablet. Treatments were separated by a 7-day washout period. Peak concentrations did not differ between CT and SR treatments, although area under the concentration-time curve (AUC) of alprazolam was greater after administration of SR than after CT, because plateau concentrations were attained after SR. Both SEM and psychomotor tests showed time-dependent responses consistent with the development of tolerance. SEMs discriminated the differences in rate of drug input of the CT and SR formulations, with impairment evident at low concentrations during absorption. SEM impairment also persisted longer than did psychomotor impairment. Peak saccade velocity is a more sensitive indicator of pharmacologic effects mediated by the GABA- benzodiazepine receptor complex than are psychomotor responses. This is probably the result of the very high GABA dependency of SEMs, along with their limited sensitivity to motivation.

AB - The purpose of this study was to determine whether short-term tolerance develops to GABA-agonist-induced changes in saccadic eye movements (SEMs), and whether the time course for GABA-agonist induced onset and offset of impairment is similar for SEMs and for psychomotor function. An additional goal was to determine whether there are differences in sensitivity between SEMs and psychomotor function. Six healthy volunteers participated in this balanced double-blind, three-way crossover, single-dose study of placebo and two different dosage forms of the GABA-agonist alprazolam: a rapidly absorbed oral 1.5-mg compressed tablet (CT) and a 3.0-mg sustained release (SR) tablet. Treatments were separated by a 7-day washout period. Peak concentrations did not differ between CT and SR treatments, although area under the concentration-time curve (AUC) of alprazolam was greater after administration of SR than after CT, because plateau concentrations were attained after SR. Both SEM and psychomotor tests showed time-dependent responses consistent with the development of tolerance. SEMs discriminated the differences in rate of drug input of the CT and SR formulations, with impairment evident at low concentrations during absorption. SEM impairment also persisted longer than did psychomotor impairment. Peak saccade velocity is a more sensitive indicator of pharmacologic effects mediated by the GABA- benzodiazepine receptor complex than are psychomotor responses. This is probably the result of the very high GABA dependency of SEMs, along with their limited sensitivity to motivation.

UR - http://www.scopus.com/inward/record.url?scp=0031925198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031925198&partnerID=8YFLogxK

M3 - Article

C2 - 9590461

AN - SCOPUS:0031925198

VL - 38

SP - 337

EP - 346

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 4

ER -